

Bio-Techne and CST partner to validate simple western antibodies

16 February 2023 | News

To help scientists get groundbreaking results even faster



US-headquartered firms Bio-Techne Corporation and Cell Signaling Technology (CST) have announced the addition of Simple Western validation to CST antibodies. This will allow researchers in various disciplines an easier way to study important molecular signaling pathways on a trusted and validated platform.

Obtaining accurate data efficiently and fast is key to advancing drug discovery and development. This ongoing partnership will allow for an expanded menu of Simple Western validated antibodies for various targets across multiple disciplines.

Simple Western systems from ProteinSimple, a Bio-Techne brand, are the only fully automated western blotting solutions for protein detection and characterisation, providing results in as little as 3 hours.

CST is a leader in the development of antibodies and other related reagents used to elucidate cell signaling pathways that dictate cellular behavior and impact human health. CST has completed assay optimization and validation on the Simple Western platform for a number of their antibodies, making it easier than ever to develop new robust and quantitative immunoassays for the detection and quantification of phospho and total proteins.

Researchers who choose CST primary antibodies with Simple Western validation can simply dilute the antibody to the recommended dilution range found on the data sheet and product page. CST antibodies are compatible with the standard Simple Western protocol, which helps users seamlessly incorporate these rigorously validated antibodies into their existing workflows.